About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Recurrence Risk Evaluation by 21-gene Detection

NCT03841266·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Xijing Hospital

Age

18–70

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

1. breast cancer in stage I-III, tumor size\>0.5cm
2. lymph nodes negative
3. hormone receptor positive （ER+/PR+,ER+/PR-,ER-/PR+）
4. HER2 negative（IHC 0 or +， FISH negative）
5. receive endocrine therapy only
6. enough FFPE samples within 10 years（3\~6 10μm ）
7. patients with integrated medical records

You may not be if

1. Tumor cells \<5%
2. Isolated RNA\<500ng

The record

StatusCompleted

PhaseNo phase

Taking part220

StartedJan 2019

UpdatedFeb 15, 2019

Conditions

Relationship and Consistency Analysis

Where1

Xijing hoapital
Xi'an, China

Clareo Health | Recurrence Risk Evaluation by 21-gene Detection